Vaping
Conditions
Keywords
electronic cigarettes, vaping, e-cigarettes
Brief summary
Researchers are gathering information on the feasibility of treating e-cigarette users with 12-weeks of varenicline (Chantix®) in assisting with stopping the use of e-cigarettes.
Detailed description
Because the process of developing nicotine dependence and the reinforcing mechanisms of nicotine delivered in high concentrations are similar between tobacco cigarettes and newer generation electronic cigarettes, the investigators hypothesize that evidence based treatment approaches used in treating tobacco dependence should be effective in treating dependence on electronic cigarettes. Since there is no existing evidence base for treatment of electronic cigarette dependence, preliminary evidence is needed from feasibility and open label studies to guide in the development of future randomized clinical trials. In this study, vaping participants will be treated with a 12 week course of varenicline as well as have nicotine dependence counseling through a certified tobacco treatment specialist followed up 12 weeks post end of medication.
Interventions
DRUGVarenicline
Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
brief behavioral therapy
Sponsors
Mayo Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
12 weeks of varenicline
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* ≥18 years and ≤65 years of age; * No use of tobacco in any form (except E-cigarettes) in the past 3 months; * currently using e-cigarettes
Exclusion criteria
* Current moderate or severe depression * Use of any treatments for tobacco dependence within the past 30 days; * Recent history (past 3 months) of abuse of, or dependence on, a substance other than nicotine; * Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase, or a male who is able to father a child, and are not willing to use a reliable form of contraception, * Subject describes having a medical history of: a) unstable angina; b) myocardial infarction within the past 3 months; c) coronary angioplasty; or d) an untreated cardiac dysrhythmia; * Subject currently has cancer \[excluding non-melanoma skin cancer\] not in remission; * Known allergy to varenicline; * Subject has a medical condition deemed by the investigators to be exclusionary to the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of e-cigarette abstinence after 12 weeks of treatment with varenicline plus brief behavioral therapy as an aid to stop vaping | 12 weeks | The rate of self reported e-cigarette abstinence verified biochemically with nicotine and nicotine metabolites in urine will be assessed at the end of a 12-week course of varenicline plus brief behavioral therapy. |
Outcome results
None listed